Literature DB >> 15771959

Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.

Almudena Hurtado Picó1, Xiaomin Wang, Isaac Sipo, Ulrike Siemetzki, Jürgen Eberle, Wolfgang Poller, Henry Fechner.   

Abstract

Restricted replication-competent adenoviruses (RRCAs) using tumor- and tissue-specific promoters (ttsP's) are new tools for cancer gene therapy. In this study we investigated viral and nonviral factors affecting "leakiness" of several ttsP's and their relevance for nonspecific ttsP-dependent RRCA (ttsP-RRCA) replication. The leakiness of the ttsP's in nontarget cells was per se highly variable and correlated with levels of nonspecific ttsP-RRCA replication. Transcriptional regulator elements fused to ttsP's showed variable effects: a hypoxic response element reduced leakiness of an alpha-fetoprotein promoter. In contrast, a mouse tyrosinase enhancer increased leakiness of a tyrosinase promoter, although it was not affected by a human tyrosinase enhancer. Furthermore, leakiness of ttsP's was enhanced by 5'-terminal adenoviral E1A enhancers, and adenoviral E1A-13S was found to be a strong transactivator of ttsP's, leading to "autoactivation" of leaky ttsP-RRCAs. In a proof-of-principle study, ttsP-RRCA replication was shown to be inhibited by a tetracycline-controlled transcriptional silencer via direct ttsP silencing. This opens up the prospect of pharmacological regulation of ttsP-RRCAs. Together, these data indicate that leakiness of ttsP's induced by several factors is a major cause of nonspecific ttsP-RRCA replication. Consideration of these factors may help optimize ttsP-dependent RRCA vectors and may thereby improve their safety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771959     DOI: 10.1016/j.ymthe.2004.10.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  9 in total

1.  An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Authors:  Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

2.  Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.

Authors:  Engin Gürlevik; Norman Woller; Nina Strüver; Peter Schache; Arnold Kloos; Michael P Manns; Lars Zender; Florian Kühnel; Stefan Kubicka
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

3.  Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy.

Authors:  Sunetra Ray; Ramasamy Paulmurugan; Manish R Patel; Byeong C Ahn; Lily Wu; Michael Carey; Sanjiv S Gambhir
Journal:  Mol Ther       Date:  2008-09-02       Impact factor: 11.454

Review 4.  Gene therapy for gastric cancer: is it promising?

Authors:  Andreas P Sutter; Henry Fechner
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

Review 5.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

6.  Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.

Authors:  Florian Kühnel; Engin Gürlevik; Thomas C Wirth; Nina Strüver; Nisar P Malek; Martina Müller-Schilling; Michael P Manns; Amancio Carnero; Lars Zender; Stefan Kubicka
Journal:  Mol Ther       Date:  2009-12-29       Impact factor: 11.454

7.  Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication.

Authors:  Engin Gürlevik; Peter Schache; Anneliese Goez; Arnold Kloos; Norman Woller; Nina Armbrecht; Michael P Manns; Stefan Kubicka; Florian Kühnel
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

8.  Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell.

Authors:  Li Liu; Jiabin Ma; Lanyi Qin; Xiaogang Shi; Hongqiang Si; Yahui Wei
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Generation of a tumor- and tissue-specific episomal non-viral vector system.

Authors:  Rudolf Haase; Terese Magnusson; Baowei Su; Florian Kopp; Ernst Wagner; Hans Lipps; Armin Baiker; Manfred Ogris
Journal:  BMC Biotechnol       Date:  2013-06-04       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.